IDEXX Laboratories, Inc. — Q3 2021 Form 10-Q Summary
Business context and reporting period
Unaudited results cover the three and nine months ended September 30, 2021, compared with the corresponding 2020 periods. IDEXX provides veterinary diagnostics and information technology, water-quality testing products, livestock, poultry and dairy diagnostics, and human medical diagnostics through its Companion Animal Group (CAG), Water, Livestock, Poultry and Dairy (LPD), and Other segments.
Key financial metrics
| Metric | Q3 2021 | Q3 2020 | 9M 2021 | 9M 2020 |
|---|---|---|---|---|
| Revenue | $810.4 million | $721.8 million | $2.414 billion | $1.986 billion |
| Reported revenue growth | 12.3% | — | 21.6% | — |
| Organic revenue growth | 10.2% | — | 18.5% | — |
| Gross profit | $472.9 million | $422.6 million | $1.433 billion | $1.162 billion |
| Gross margin | 58.4% | 58.5% | 59.4% | 58.5% |
| Operating income | $226.0 million | $171.9 million | $732.8 million | $509.4 million |
| Operating margin | 27.9% | 23.8% | 30.4% | 25.7% |
| Net income attributable to IDEXX | $175.2 million | $146.2 million | $582.1 million | $407.0 million |
| Diluted EPS | $2.03 | $1.69 | $6.71 | $4.70 |
Q3 net margin was approximately 21.6%; nine-month net margin was approximately 24.1%. Operating cash flow for the nine months was $545.6 million, compared with $429.1 million in the prior-year period. Capital expenditures were $87.8 million, acquisitions used $161.2 million, and full-year 2021 capital spending was expected to be approximately $150 million.
At September 30, 2021, cash and cash equivalents were $145.2 million, working capital was $304.2 million, and total debt was approximately $853.0 million. The company had no borrowings under its $1.0 billion revolving credit facility and $998.6 million of availability, net of letters of credit. Gross debt to Adjusted EBITDA was 0.81x and net debt to Adjusted EBITDA was 0.67x. The company was in compliance with its 3.5x leverage covenant.
Material changes versus the prior comparable period
- CAG revenue increased 14.8% in Q3 and 23.6% for the nine months; organic growth was 12.7% and 20.6%, respectively. Growth was led by recurring diagnostics, consumables, reference laboratory services, instrument placements, and veterinary software.
- Water revenue increased 14.6% in Q3 and 14.5% for the nine months, reflecting recovery in testing volumes and price increases.
- LPD revenue declined 21.2% in Q3 and 1.4% for the nine months, primarily because of lower swine testing in China following unusually high African Swine Fever testing in the prior year.
- Other-segment Q3 revenue declined 21.2%, primarily because of lower demand for OPTI COVID-19 PCR products and services. Nine-month Other revenue increased 4.6%, but gross margin declined because of excess COVID-19 testing inventory write-downs and lower royalty revenue.
- Operating margin improved substantially because revenue growth and operating leverage more than offset higher sales, marketing, research and development, freight, and laboratory investment costs. General and administrative expense benefited from the absence of a prior-year litigation accrual and charitable donation.
- Cash declined by $238.7 million during the nine months, principally because of $502.0 million of common-stock repurchases, $161.2 million of acquisitions, capital spending, and repayment of $50.0 million of senior notes.
- The company acquired ezyVet, VetRadar, a Swiss reference laboratory, and a teleradiology business during 2021 for aggregate disclosed consideration of approximately $168.1 million, including contingent amounts.
Guidance, outlook, risks, contingencies and unusual items
- The filing provides capital-spending outlook of approximately $150 million for 2021, but does not provide a clear full-year revenue or earnings guidance figure.
- Management expects supply-chain, logistics, product-availability, and inflationary pressures to continue into 2022, although it believes mitigation efforts have maintained product availability and customer service.
- Management expects LPD revenue pressure in China to continue because of lower pork prices, relaxed African Swine Fever controls, and changing government requirements.
- Future OPTI COVID-19 testing demand is expected to remain below prior-period levels, but demand is difficult to forecast because of variants, vaccination rates, testing requirements, and competing suppliers.
- A litigation matter involves an alleged underpayment of royalties under an expired patent license. The plaintiff claims approximately $50 million; IDEXX accrued $27.5 million in 2020, is appealing an adverse trial-court ruling, and states that the ultimate outcome may be higher or lower than the accrual.
- Potential changes to U.S. and international tax rules, including global minimum-tax proposals, and the expiration of a Netherlands tax ruling on December 31, 2022, could increase the effective tax rate and tax liabilities.
- The Q3 effective tax rate increased to 20.0% from 10.8%; the nine-month rate increased to 18.1% from 16.0%, primarily because of lower share-based compensation tax benefits and resolution of uncertain tax positions.
- Operating-type reagent rental assets incurred impairment charges of $1.3 million in Q3 and $5.1 million for the nine months. The company also recognized higher costs associated with excess COVID-19 testing inventory.
Important facts for investors to verify
- Whether CAG recurring diagnostic growth and veterinary clinical-visit trends remain durable as comparisons normalize after pandemic-related demand effects.
- The pace and duration of LPD revenue declines in China and the sensitivity of results to African Swine Fever testing demand and pork-market conditions.
- The effect of supply-chain constraints, freight costs, inflation, and laboratory investments on gross margins.
- The actual 2021 revenue, earnings, foreign-currency, and capital-spending outlook, which is not fully specified in the filing.
- The resolution and eventual cash impact of the royalty litigation and the $27.5 million accrual.
- The impact of Netherlands tax-rule changes and broader international tax reforms on future effective tax rates.
- Liquidity after the $75 million of senior notes due February 12, 2022, continued share repurchases, acquisitions, and planned capital expenditures.